Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|October 19, 2017
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF InhibitorsDafna Gladman, William Rigby, Valderilio F Azevedo, et al.
Rheumatology and Therapy|September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation AnalysisKurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.
BMC Pharmacology & Toxicology|September 23, 2015
Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritisPaulo Cm Urbano, Vanete T Soccol, Vivian N Teixeira, et al.
Rheumatology and Therapy|September 27, 2021
Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online SurveyLaura C Coates, Valderilio F Azevedo, Joseph C Cappelleri, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
The Journal of Allergy and Clinical Immunology|December 18, 2017
TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expressionPaulo C M Urbano, Raúl Aguirre-Gamboa, Angel Ashikov, et al.
Drug Safety|February 2, 2020
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational DataGerd R Burmester, Jeffrey R Curtis, Huifeng Yun, et al.
The Journal of Rheumatology|May 3, 2017
Proceedings of the GRAPPA 2016 RetreatDeepak R Jadon, Dafna D Gladman, Philip J Mease, et al.
Clinical and Experimental Rheumatology|August 1, 2013
An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA GroupPercival D Sampaio-Barros, Ivanio A Pereira, Claudia Hernández-Cuevas, et al.
The Lancet. Gastroenterology & Hepatology|January 20, 2022
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel DiseasesLucas Guillo, Maria Abreu, Remo Panaccione, et al.
Pageof 3